As of today (2024-04-30), Omeros's share price is $3.16. Omeros's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $-0.41. Hence, Omeros's Price to Tangible Book Ratio of today is .
The historical rank and industry rank for Omeros's Price-to-Tangible-Book or its related term are showing as below:
During the past 13 years, Omeros's highest Price to Tangible Book Ratio was 16.92. The lowest was 1.66. And the median was 9.29.
OMER's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.69 * Ranked among companies with meaningful Price-to-Tangible-Book only.
A closely related ratio is called PB Ratio. As of today, Omeros's share price is $3.16. Omeros's Book Value per Sharefor the quarter that ended in Dec. 2023 was $-0.41. Hence, Omeros's P/B Ratio of today is .
Omeros Price-to-Tangible-Book Historical Data
The historical data trend for Omeros's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Omeros's Price-to-Tangible-Book
For the Biotechnology subindustry, Omeros's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Omeros's Price-to-Tangible-Book Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Omeros's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Omeros's Price-to-Tangible-Book falls into.
Omeros Price-to-Tangible-Book Calculation
Omeros's price-to-tangible-book ratio for today is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Omeros Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Omeros's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OMER has been successfully added to your 